Gemphire Therapeutics Provides the American Liver Foundation an Educational Grant in Support of Disease State Awareness for P...
May 18 2018 - 9:29AM
Webinar on Wednesday, May 23, at 8:00am Eastern
Time
Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage
biopharmaceutical company focused on developing and commercializing
therapies for cardiometabolic disorders, including non-alcoholic
fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH)
and dyslipidemia, is sponsoring via an educational grant the
American Liver Foundation’s (ALF) upcoming webinar "Pediatric
Non-Alcoholic Fatty Liver Disease—Yes, It Absolutely Starts in
Childhood” on Wednesday, May 23. The American Liver Foundation is a
non-profit organization that facilitates, advocates, and promotes
education, support, and research for the prevention, treatment, and
cure of liver disease.
“We are delighted to provide an educational grant to help
support the ALF’s webinar on pediatric NAFLD and to promote a
better comprehension of NAFLD origin and treatment options,” said
Lee Golden, M.D., Chief Medical Officer of Gemphire. “We believe
that our novel lipid-altering product candidate, gemcabene, has
potential to be a highly differentiated treatment for pediatric and
adult NAFLD/NASH patients in a market in critical need of better
therapeutic options for chronic liver disease.”
Webinar Details
Title: |
Pediatric Non-Alcoholic Fatty Liver Disease—Yes, It Absolutely
Starts in Childhood |
Date: |
Wednesday, May 23 |
Time: |
8:00am –
9:00am Eastern Time |
Presenters: |
Dr.
Miriam Vos, Assistant Professor of Pediatrics, Emory University
School of Medicine; Dr. Saul Karpen, Professor of Pediatrics,
Raymond F. Schinazi Distinguished Biomedical Chair, Chief of the
Division of Pediatric Gastroenterology, Hepatology and Nutrition at
Emory University School of Medicine/Children's Healthcare of
Atlanta; Tom Nealon, President & CEO, The American Liver
Foundation |
Registration Link: |
https://register.gotowebinar.com/register/6667421309075083267 |
The hour-long webinar provides an opportunity for general
practitioners and pediatricians to receive an in-depth
understanding of Pediatric NAFLD. The presenters will be discussing
obesity trends and contributing factors, how pediatric and adult
NAFLD/NASH perspectives differ from a provider's perspective, key
underlying metabolic issues associated with Pediatric NAFLD,
current treatment options, future direction of research, and
resources available to providers and their patients. Mr. Nealon
will be speaking on the webinar along with Dr. Miriam Vos, an
Assistant Professor of Pediatrics at Emory University School of
Medicine, and Dr. Saul Karpen, a Professor of Pediatrics at Emory
University School of Medicine/Children's Healthcare of Atlanta.
Gemphire is currently enrolling patients in a Phase 2a
proof-of-concept clinical trial investigating gemcabene as a
treatment for pediatric NAFLD. The trial is part of a broader
program to develop gemcabene in NAFLD/NASH and is running in
parallel with the recently initiated clinical trial investigating
gemcabene in familial partial lipodystrophy (FPL). Top line
results from the pediatric NAFLD trial are expected in early 2019.
More information on both trials can be found at
www.clinicaltrials.gov.
About the American Liver Foundation Founded in
1976, the American Liver Foundation (ALF) is the nation’s largest
patient advocacy organization for people with liver disease. ALF
reaches more than two million individuals each year with health
information, education and support services via its national
office, U.S. divisions and an active online presence. Recognized as
a trusted voice for individuals living with liver disease, ALF also
operates a toll-free National Helpline (1-800-GO-LIVER); educates
patients, policymakers and the public; and provides grants to
early-career researchers to help find a cure for all liver
diseases. Please visit www.liverfoundation.org for more information
and resources.
About GemphireGemphire is a clinical-stage
biopharmaceutical company that is committed to helping patients
with cardiometabolic disorders, including dyslipidemia and NASH.
The Company is focused on providing new treatment options for
cardiometabolic diseases through its complementary, convenient,
cost-effective product candidate gemcabene as add-on to the
standard of care, especially statins, that will benefit patients,
physicians, and payors. Gemphire’s Phase 2 clinical program is
evaluating the efficacy and safety of gemcabene in
hypercholesterolemia, including FH and ASCVD, SHTG and
NASH/NAFLD. Two trials supporting hypercholesterolemia have
been completed under NCT02722408 and NCT02634151. Gemphire
has completed recruitment for a clinical trial for SHTG under
NCT02944383, and has initiated separate trials for adult NASH and
pediatric NAFLD. Please visit www.gemphire.com for more
information.
Forward Looking Statements Any statements
in this press release about Gemphire’s future expectations,
milestones, goals, plans and prospects, including statements about
Gemphire’s financial prospects, future operations and sufficiency
of funds for future operations, clinical development of Gemphire’s
product candidate, expectations regarding future clinical trials
(including the timing of the announcement of top-line results),
regulatory developments, submissions and meetings and future
expectations and plans and prospects for gemcabene and Gemphire,
expectations for the future competitive environment for
gemcabene, expectations regarding operating expenses and cash
used in operations, and other statements containing the words
"believes," "anticipates," "estimates," "expects," "intends,"
"plans," "predicts," "projects," "targets," "may," "potential,"
"will," "would," "could," "should," "continue," “scheduled” and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: developments in the capital markets,
the success and timing of Gemphire’s regulatory submissions and
pre-clinical and clinical trials; regulatory requirements or
developments; changes to Gemphire’s clinical trial designs and
regulatory pathways; timing of enrollment of patients in our
clinical trials; changes in Gemphire’s capital resource
requirements; the actions of Gemphire’s competitors; Gemphire’s
ability to obtain additional financing; Gemphire’s ability to
successfully market and distribute its product candidate, if
approved; Gemphire’s ability to obtain and maintain its
intellectual property protection; and other factors discussed in
the "Risk Factors" section of Gemphire’s annual report, and in
other filings Gemphire makes with the SEC from time to time.
In addition, the forward-looking statements included in this press
release represent Gemphire’s views as of the date hereof. Gemphire
anticipates that subsequent events and developments will cause
Gemphire’s views to change. However, while Gemphire may elect to
update these forward-looking statements at some point in the
future, Gemphire specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing Gemphire’s views as of any date subsequent to the date
hereof.
Contact:Andrew McDonald, Ph.D.LifeSci Advisors,
LLC(646) 597-6987
Jeff Mathiesen, CFOGemphire Therapeutics Inc.(734)-245-1700
Gemphire Therapeutics (NASDAQ:GEMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gemphire Therapeutics (NASDAQ:GEMP)
Historical Stock Chart
From Sep 2023 to Sep 2024